An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

MUSCAT: The National Programme for Early Detection of Diabetic Retinopathy using artificial intelligence (AI) technologies ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

In an era where chronic diseases are reshaping global health priorities, the diabetic retinopathy market stands out as a ...

Eye floaters, those drifting spots in your vision, are often harmless but can signal hypertension or diabetes. High blood ...

The agreement is for a planned clinical trial of AXPAXLI (also known as OTX-TKI) for the treatment of non-proliferative ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Drugs such as Ozempic, Wegovy, and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...